CoChat
Sign Up
Cited by 107

The DOI matches its Crossref record.

Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]

Cain, William J., Millar, John S., Himebauch, Adam S., Tietge, Uwe J.F., Maugeais, Cyrille, Usher, David, Rader, Daniel J.·2005·Journal of Lipid Research
DOI 10.1194/jlr.m500249-jlr200
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1194/jlr.m500249-jlr200

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Steady state levels of circulating Lp(a) depend on its rate of clearance, which occurs primarily in the liver.

    “The steady state level of circulating Lp(a) also depends on its rate of clearance, which occurs primarily in the liver25,26.”

    From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [25]

  • Multiple studies of LDLR in cells, animal models, and humans have provided inconsistent or conflicting results.

    “Multiple studies of the LDL receptor (LDLR) in cells27-34, animal models25,32,35,36, and humans10,28,37-48 have provided inconsistent or conflicting results.”

    From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [25]

  • Studies of mice catabolism of exogenous human Lp(a) have yielded mixed results, with some demonstrating LDLR-dependent and some LDLR-independent clearance.

    “Although mice do not produce endogenous Lp(a), studies of their catabolism of exogenous human Lp(a) have also yielded mixed results, with some demonstrating LDLR-dependent35,36 and some LDLR-independent25,32 clearance.”

    From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [25]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 57

  1. Scanu, 2001, The role of lipoprotein(a) in the pathogenesis of atherosclerotic cardiovascular disease and its utility as predictor of coronary heart disease events, Curr. Cardiol. Rep., 3, 385, 10.1007/s11886-001-0055-4 · DOI
  2. Hobbs, 1999, Lipoprotein(a): intrigues and insights, Curr. Opin. Lipidol., 10, 225, 10.1097/00041433-199906000-00005 · DOI
  3. Rader, 1994, The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate, J. Clin. Invest., 93, 2758, 10.1172/JCI117292 · DOI
  4. Rader, 1993, Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production, J. Clin. Invest., 91, 443, 10.1172/JCI116221 · DOI
  5. Boerwinkle, 1992, Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations, J. Clin. Invest., 90, 52, 10.1172/JCI115855 · DOI
  6. Koschinsky, 2004, Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity, Curr. Opin. Lipidol., 15, 167, 10.1097/00041433-200404000-00009 · DOI
  7. Kostner, 1998, Decreased urinary apolipoprotein (a) excretion in patients with impaired renal function, Eur. J. Clin. Invest., 28, 447, 10.1046/j.1365-2362.1998.00319.x · DOI
  8. Sechi, 1998, Increased serum lipoprotein(a) levels in patients with early renal failure, Ann. Intern. Med., 129, 457, 10.7326/0003-4819-129-6-199809150-00006 · DOI
  9. Kronenberg, 1997, Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation, J. Lipid Res., 38, 1755, 10.1016/S0022-2275(20)37150-9 · DOI
  10. Wiklund, 1990, Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia, Lancet., 335, 1360, 10.1016/0140-6736(90)91242-3 · DOI
  11. Floren, 1981, Uptake of Lp (a) lipoprotein by cultured fibroblasts, Biochem. Biophys. Res. Commun., 102, 636, 10.1016/S0006-291X(81)80179-9 · DOI · Paper page
  12. Krempler, 1983, Studies on the role of specific cell surface receptors in the removal of lipoprotein (a) in man, J. Clin. Invest., 71, 1431, 10.1172/JCI110896 · DOI · Paper page
  13. Havekes, 1981, Binding of Lp(a) to the low density lipoprotein receptor of human fibroblasts, FEBS Lett., 132, 169, 10.1016/0014-5793(81)81153-2 · DOI
  14. Mbewu, 1991, Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations, Arterioscler. Thromb., 11, 940, 10.1161/01.ATV.11.4.940 · DOI
  15. Utermann, 1989, Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis, Proc. Natl. Acad. Sci. USA., 86, 4171, 10.1073/pnas.86.11.4171 · DOI
  16. Niemeier, 1999, Identification of megalin/gp330 as a receptor for lipoprotein(a) in vitro, Arterioscler. Thromb. Vasc. Biol., 19, 552, 10.1161/01.ATV.19.3.552 · DOI
  17. Marz, 1993, Heterogeneous lipoprotein (a) size isoforms differ by their interaction with the low density lipoprotein receptor and the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor, FEBS Lett., 325, 271, 10.1016/0014-5793(93)81087-G · DOI · Paper page
  18. Argraves, 1997, The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor, J. Clin. Invest., 100, 2170, 10.1172/JCI119753 · DOI · Paper page
  19. Mahley, 1999, Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E, J. Lipid Res., 40, 1, 10.1016/S0022-2275(20)33334-4 · DOI · Paper page
  20. van Barlingen, 1997, Lipoprotein lipase-enhanced binding of lipoprotein(a) [Lp(a)] to heparan sulfate is improved by apolipoprotein E (apoE) saturation: secretion-capture process of apoE is a possible route for the catabolism of Lp(a), Metabolism., 46, 650, 10.1016/S0026-0495(97)90008-1 · DOI
  21. Rader, 1995, The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans, J. Clin. Invest., 95, 1403, 10.1172/JCI117794 · DOI · Paper page
  22. Edelstein, 1995, Determinants of lipoprotein(a) assembly: a study of wild-type and mutant apolipoprotein(a) phenotypes isolated from human and rhesus monkey lipoprotein(a) under mild reductive conditions, Biochemistry., 34, 16483, 10.1021/bi00050a032 · DOI
  23. Pittman, 1986, Methods for assessment of tissue sites of lipoprotein degradation, Methods Enzymol., 129, 612, 10.1016/0076-6879(86)29094-1 · DOI
  24. Brown, 1997, Physiological parameter values for physiologically based pharmacokinetic models, Toxicol. Ind. Health., 13, 407, 10.1177/074823379701300401 · DOI
  25. Hrzenjak, 2003, Galactose-specific asialoglycoprotein receptor is involved in lipoprotein (a) catabolism, Biochem. J., 376, 765, 10.1042/bj20030932 · DOI · Paper page
  26. Lawn, 1995, The recurring evolution of lipoprotein(a). Insights from cloning of hedgehog apolipoprotein(a), J. Biol. Chem., 270, 24004, 10.1074/jbc.270.41.24004 · DOI
  27. Callow, 1994, Expression of human apolipoprotein B and assembly of lipoprotein(a) in transgenic mice, Proc. Natl. Acad. Sci. USA., 91, 2130, 10.1073/pnas.91.6.2130 · DOI
  28. Cheesman, 2000, An analysis of the interaction between mouse apolipoprotein B100 and apolipoprotein(a), J. Biol. Chem., 275, 28195, 10.1074/jbc.M002772200 · DOI
  29. Chiesa, 1992, Reconstitution of lipoprotein(a) by infusion of human low density lipoprotein into transgenic mice expressing human apolipoprotein(a), J. Biol. Chem., 267, 24369, 10.1016/S0021-9258(18)35775-2 · DOI
  30. Linton, 1993, Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a), J. Clin. Invest., 92, 3029, 10.1172/JCI116927 · DOI
  31. Callow, 1995, Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a), J. Clin. Invest., 96, 1639, 10.1172/JCI118203 · DOI
  32. Lawn, 1992, Atherogenesis in transgenic mice expressing human apolipoprotein(a), Nature., 360, 670, 10.1038/360670a0 · DOI
  33. Sanan, 1998, Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: no accentuation by apolipoprotein(a), Proc. Natl. Acad. Sci. USA., 95, 4544, 10.1073/pnas.95.8.4544 · DOI
  34. Gabelli, 1986, Abnormal low density lipoprotein metabolism in apolipoprotein E deficiency, J. Lipid Res., 27, 326, 10.1016/S0022-2275(20)38838-6 · DOI
  35. Ye, 1988, Tissue distribution of [3H]cholesteryl linoleyl ether-labeled human Lp(a) in different rat organs, Biochim. Biophys. Acta., 963, 534, 10.1016/0005-2760(88)90322-0 · DOI
  36. Kronenberg, 2003, Apolipoprotein(a) isoform-specific changes of lipoprotein(a) after kidney transplantation, Eur. J. Hum. Genet., 11, 693, 10.1038/sj.ejhg.5201016 · DOI
  37. Kronenberg, 2004, The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome, Kidney Int., 65, 606, 10.1111/j.1523-1755.2004.00418.x · DOI
  38. Mooser, 1996, Apolipoprotein(a) kringle 4-containing fragments in human urine. Relationship to plasma levels of lipoprotein(a), J. Clin. Invest., 97, 858, 10.1172/JCI118487 · DOI
  39. Oida, 1992, Apolipoprotein(a) is present in urine and its excretion is decreased in patients with renal failure, Clin. Chem., 38, 2244, 10.1093/clinchem/38.11.2244 · DOI
  40. Doucet, 2000, Lipoprotein(a) in the nephrotic syndrome: molecular analysis of lipoprotein(a) and apolipoprotein(a) fragments in plasma and urine, J. Am. Soc. Nephrol., 11, 507, 10.1681/ASN.V113507 · DOI
  41. Mooser, 1996, Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine, J. Clin. Invest., 98, 2414, 10.1172/JCI119055 · DOI
  42. Armstrong, 1990, Heterogeneity of human lipoprotein Lp[a]: cytochemical and biochemical studies on the interaction of two Lp[a] species with the LDL receptor, J. Lipid Res., 31, 429, 10.1016/S0022-2275(20)43165-7 · DOI
  43. Maartmann-Moe, 1981, Lp(a) lipoprotein enters cultured fibroblasts independently of the plasma membrane low density lipoprotein receptor, Clin. Genet., 20, 352, 10.1111/j.1399-0004.1981.tb01047.x · DOI
  44. Reblin, 1997, Cellular uptake of lipoprotein[a] by mouse embryonic fibroblasts via the LDL receptor and the LDL receptor-related protein, J. Lipid Res., 38, 2103, 10.1016/S0022-2275(20)37140-6 · DOI · Paper page
  45. Perombelon, 1992, Lipoprotein(a) in subjects with familial defective apolipoprotein B100, Atherosclerosis., 92, 203, 10.1016/0021-9150(92)90279-P · DOI
  46. Hofmann, 1990, Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice, J. Clin. Invest., 85, 1542, 10.1172/JCI114602 · DOI · Paper page
  47. Ramharack, 1999, Recombinant adenovirus vector mediated expression of lipoprotein (a) [Lp(a)] in rabbit plasma, Biochim. Biophys. Acta., 1438, 322, 10.1016/S1388-1981(99)00065-7 · DOI
  48. Fan, 2000, Defects of the LDL receptor in WHHL transgenic rabbits lead to a marked accumulation of plasma lipoprotein [a], J. Lipid Res., 41, 1004, 10.1016/S0022-2275(20)32043-5 · DOI
  49. Woollett, 1995, Apolipoprotein E competitively inhibits receptor-dependent low density lipoprotein uptake by the liver but has no effect on cholesterol absorption or synthesis in the mouse, Proc. Natl. Acad. Sci. USA., 92, 12500, 10.1073/pnas.92.26.12500 · DOI
  50. Tiebel, 1999, Mouse very low-density lipoprotein receptor (VLDLR): gene structure, tissue-specific expression and dietary and developmental regulation, Atherosclerosis., 145, 239, 10.1016/S0021-9150(99)00068-4 · DOI
  51. Zheng, 1994, Organ distribution in rats of two members of the low-density lipoprotein receptor gene family, gp330 and LRP/alpa 2MR, and the receptor-associated protein (RAP), J. Histochem. Cytochem., 42, 531, 10.1177/42.4.7510321 · DOI
  52. Bottalico, 1993, Cholesterol loading of macrophages leads to marked enhancement of native lipoprotein(a) and apoprotein(a) internalization and degradation, J. Biol. Chem., 268, 8569, 10.1016/S0021-9258(18)52913-6 · DOI
  53. Fless, 1986, Physicochemical properties of apolipoprotein(a) and lipoprotein(a) derived from the dissociation of human plasma lipoprotein (a), J. Biol. Chem., 261, 8712, 10.1016/S0021-9258(19)84439-3 · DOI
  54. Spiess, 1990, The asialoglycoprotein receptor: a model for endocytic transport receptors, Biochemistry., 29, 10009, 10.1021/bi00495a001 · DOI
  55. Wu, 1998, Increased liver uptake of liposomes and improved targeting efficacy by labeling with asialofetuin in rodents, Hepatology., 27, 772, 10.1002/hep.510270319 · DOI
  56. Keesler, 1996, The binding activity of the macrophage lipoprotein(a)/apolipoprotein(a) receptor is induced by cholesterol via a post-translational mechanism and recognizes distinct kringle domains on apolipoprotein(a), J. Biol. Chem., 271, 32096, 10.1074/jbc.271.50.32096 · DOI
  57. Devlin, 2005, An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo, Arterioscler. Thromb. Vasc. Biol., 25, 1704, 10.1161/01.ATV.0000170819.57945.03 · DOI

Cited by

Sorted by citations

Metadata

Authors
Cain, W. J., Millar, J. S., Himebauch, A. S., Tietge, U. J. F., Maugeais, C., Usher, D., & Rader, D. J.
Venue
Journal of Lipid Research
Publisher
Elsevier BV
Published
2005-12
Volume
46
Issue
12
Pages
2681-2691
ISSN
0022-2275
DOI
10.1194/jlr.m500249-jlr200
Cited by
107
References
0
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review